This study consists of Part A and Part B. In Part A, subjects will undergo surgical excisions in the abdominoplasty area and will be treated with MRG-001 or placebo for 3 weeks. In Part B, the excision area is harvested for analysis and the abdominoplasty is performed and the subjects is rerandomized to MRG-001 or placebo again and treated for 3 weeks. The abdominoplasty scar is then monitored for 6 months.
Surgical excisions are one of the most frequent cutaneous wounds. This study will compare the safety and preliminary efficacy of a novel fixed-dose combination drug MRG-001 in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing elective abdominoplasty.